Who is sponsoring NCT03929120?

NCT03929120 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03929120?

Interventions in NCT03929120: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs).

What condition does NCT03929120 study?

NCT03929120 studies Interstitial Lung Disease, Connective Tissue Diseases.

Is NCT03929120 still recruiting?

NCT03929120 is currently completed. Last updated 7 April 2023.

Last reviewed 2023-04-07 · How we verify

NCT03929120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

Completed Phase 1 Last updated 7 April 2023

What this trial tests

Phase 1 trial testing Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) in Interstitial Lung Disease in 10 participants. Completed in 2 February 2022.

Timeline

5 November 2019

Primary endpoint
27 July 2021

2 February 2022

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	5 November 2019
Primary completion	27 July 2021
Estimated completion	2 February 2022
Sites	1 location across United States

Drugs / interventions tested

Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) — full drug profile →

Conditions studied

Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
Connective Tissue Diseases — all drugs for Connective Tissue Diseases →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 80, any sex, with Interstitial Lung Disease or Connective Tissue Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.
Chen X, Wang F, Huang Z, Wu Y, et al · · 2021 · cited 23× · PMID 34220313 · DOI 10.7150/ijms.59218
The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.
Liang M, Matteson EL, Abril A, Distler JHW. · · 2022 · cited 15× · PMID 35186127 · DOI 10.1177/1759720x221074457
Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications.
Kotani T, Saito T, Suzuka T, Matsuda S. · · 2024 · cited 13× · PMID 39026275 · DOI 10.1186/s41232-024-00348-z
Mesenchymal stem cells and pulmonary fibrosis: a bibliometric and visualization analysis of literature published between 2002 and 2021.
Yang Y, Chen Y, Liu Y, Ning Z, et al · · 2023 · cited 10× · PMID 37469875 · DOI 10.3389/fphar.2023.1136761
Advancements in mesenchymal stromal cells for treating connective tissue disease-associated interstitial lung disease: from basic research to clinical application.
Yuan J, Yang YL, Zhao YL, Xu YW, et al · · 2025 · cited 1× · PMID 40859307 · DOI 10.1186/s13287-025-04597-8

Verify or expand the search:

Other recruiting trials for Interstitial Lung Disease

Currently open trials in the same condition.

NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
NCT07254338 — Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific · recruiting
NCT07269262 — SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers · NA · recruiting
NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03929120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 7 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing